The pathologic expression of the tumor suppressor genes p53 and p16 in curettage specimens may identify high-risk endometrial carcinoma patients with a poor prognosis, according to a study in the October issue of the American Journal of Obstetrics and Gynecology.
The pathologic expression of the tumor suppressor genes p53 and p16 in curettage specimens may identify high-risk endometrial carcinoma patients with a poor prognosis, according to a study in the October issue of the American Journal of Obstetrics and Gynecology.
Ingeborg B. Engelsen, MD, of Haukeland University Hospital in Bergen, Norway, and colleagues studied preoperative curettage material from a series of 236 endometrial carcinomas.
The researchers observed pathologic expression of p53 and p16 in 24% and 25%, respectively, of the specimens. They found a significant correlation between pathologic p53 expression and postmenopausal status, high-grade, high-tumor cell proliferation, and aneuploidy. Five-year survival rates in patients with pathologic expression of p53 and p16 were 51% and 50%, respectively, compared to 85% in patients with normal expression.
Engelsen IB, Stefansson I, Akslen LA, et al. Pathologic expression of p53 or p16 in preoperative curretage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol. 2006;195:979-986.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More